Hematology Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Hematology clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 4

Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes

CardiovascularRed Blood Cell TransfusionsSex Differences+3 more
Michelle Zeller11,082 enrolled8 locationsNCT06840756
Recruiting
Not Applicable

Goal Attainment Scale in Transplantation

OncologyHematology
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna176 enrolled1 locationNCT07372690
Recruiting

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaCART TherapyBispecific Antibody+1 more
University of Zurich208 enrolled2 locationsNCT07309497
Recruiting

Population Pharmacokinetics of Anti-infectives in Critically Ill Children

Pediatric Intensive Care UnitPediatric Immuno-hematology Department
Assistance Publique - Hôpitaux de Paris3,000 enrolled1 locationNCT02539407
Recruiting
Not Applicable

Correlation Between Ultrasound-assessed Quadriceps Muscle Mass and Baseline Whole-body Densitometry Muscle Index in the Post-cancer Population (JUMP Research II)

CancerHematologyPost-cancer
Hospices Civils de Lyon55 enrolled1 locationNCT06007794
Recruiting
Not Applicable

The Right Amount of Purge Useful for Blood Sampling on PiccLine (PiccLine)

Hematology
Rennes University Hospital66 enrolled1 locationNCT05763186
Recruiting
Not Applicable

IMPACT: IMplementation of Physical Activity for Children and Adolescents on Treatment

Pediatric CancerPediatric Hematology
University of Calgary250 enrolled2 locationsNCT04956133